Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic Launches Initiative Aimed at Demonstrating Clinical Value of SomaSignal Tests

NEW YORK – SomaLogic said Thursday it has launched its SomaSignal Proteomics for Precision Medicine Initiative, which aims to lay the groundwork for clinical use of its SomaSignal proteomic tests.

The initiative aims to enable healthcare providers to use proteomic technology to make decisions at the point of care based on a patient's individual proteome signature, said Boulder, Colorado-based SomaLogic.

The company is launching clinical trials in areas including type 2 diabetes, cardiovascular disease, and cancer with Emory University, Intermountain Healthcare, CommonSpirit Health and UCHealth — a network of 12 hospitals and hundreds of physicians across Colorado, southern Wyoming, and western Nebraska — that will evaluate the usefulness of its SomaSignal tests in clinical practice.

The healthcare providers will use the tests to help assess patient health status and disease risk and also guide patient management. They will also evaluate whether use of the SomaSignal tests motivates patients to be more actively involved in their care.

The SomaSignal tests use SomaLogic's aptamer-based affinity reagents called Somamers to measure proteins in patient samples. The company launched its first SomaSignal tests in 2019, offering them at several Colorado doctors' practices. It currently offers 12 tests as laboratory-developed tests for indications including risk of major cardiovascular events in patients with and without known heart disease and the presence of excess liver fat.

"We’re excited to work with these clinical innovators who see the value of proteomics as a tool for precision medicine and medical management," Angela Bakker-Lee, SomaLogic’s executive VP for healthcare markets, said in a statement. "SomaLogic has one of the largest proprietary clinical proteomics databases and it drives our diagnostic models for addressing cardiovascular disease and other chronic conditions. We look forward to demonstrating the impact our tests can have on improving outcomes and lowering the total cost of care."

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.